Determinants of Human Immunodeficiency Virus Type 1 Resistance to Gp41-derived Inhibitory Peptides

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1998 Jan 28

PMID 9444991

Citations 170

Authors

L T Rimsky

D C Shugars

T J Matthews

Affiliations

Soon will be listed here.

Abstract

A synthetic peptide, DP178, containing amino acids 127 to 162 of the human immunodeficiency virus type 1 (HIV-1) gp41 Env glycoprotein, is a potent inhibitor of virus infection and virus mediated cell-to-cell fusion (C. Wild, T. Greenwell, and T. Matthews, AIDS Res. Hum. Retroviruses 9:1051-1053, 1993). In an effort to understand the mechanism of action of this peptide, we derived resistant variants of HIV-1(IIIB) and NL4-3 by serial virus passage in the presence of increasing doses of the peptide. Sequence analysis of the resistant isolates suggested that a contiguous 3-amino-acid sequence within the amino-terminal heptad repeat motif of gp41 was associated with resistance. Site-directed mutagenesis studies confirmed this observation and indicated that changes in two of these three residues were necessary for development of the resistant phenotype. Direct binding of DP178 to recombinant protein and synthetic peptide analogs containing the wild-type and mutant heptad repeat sequences revealed a strong correlation between DP178 binding and the biological sensitivity of the corresponding virus isolates to DP178. The results are discussed from the standpoints of the mechanism of action of DP178 and recent crystallographic information for a core structure of the gp41 ectodomain.

Citing Articles

Design of Natterins-based peptides improves antimicrobial and antiviral activities.

de Cena G, Tada D, Lucchi D, Santos T, Heras M, Juliano M Biotechnol Rep (Amst). 2025; 45:e00867.

PMID: 39758971 PMC: 11697409. DOI: 10.1016/j.btre.2024.e00867.

Structure and Interactions of HIV-1 gp41 CHR-NHR Reverse Hairpin Constructs Reveal Molecular Determinants of Antiviral Activity.

He L, McAndrew R, Barbu R, Gifford G, Halacoglu C, Drouin-Allaire C J Mol Biol. 2024; 436(16):168650.

PMID: 38866091 PMC: 11297672. DOI: 10.1016/j.jmb.2024.168650.

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Apetroaei M, Velescu B, Nedea M, Dinu-Pirvu C, Draganescu D, Faca A Biomedicines. 2024; 12(4).

PMID: 38672269 PMC: 11048092. DOI: 10.3390/biomedicines12040915.

Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities.

Zenin V, Tsedilin A, Yurkova M, Siniavin A, Fedorov A PLoS One. 2023; 18(6):e0286752.

PMID: 37289764 PMC: 10249821. DOI: 10.1371/journal.pone.0286752.

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19.

He L, Wang C, Zhang Y, Chong H, Hu X, Li D Front Immunol. 2023; 14:1199938.

PMID: 37256122 PMC: 10225588. DOI: 10.3389/fimmu.2023.1199938.

References

Neurath A, Lin K, Strick N, Jiang S . Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain. AIDS Res Hum Retroviruses. 1995; 11(2):189-90. DOI: 10.1089/aid.1995.11.189. View

Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M . Nucleotide sequence of the AIDS virus, LAV. Cell. 1985; 40(1):9-17. DOI: 10.1016/0092-8674(85)90303-4. View

Shibata R, HOGGAN M, Broscius C, Englund G, THEODORE T, Buckler-White A . Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J Virol. 1995; 69(7):4453-62. PMC: 189187. DOI: 10.1128/JVI.69.7.4453-4462.1995. View

Wild C, Greenwell T, Shugars D, Matthews T . The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses. 1995; 11(3):323-5. DOI: 10.1089/aid.1995.11.323. View

Rabenstein M, Shin Y . A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation. Biochemistry. 1995; 34(41):13390-7. DOI: 10.1021/bi00041a016. View

Lu M, Blacklow S, Kim P . A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol. 1995; 2(12):1075-82. DOI: 10.1038/nsb1295-1075. View

Shugars D, Wild C, Greenwell T, Matthews T . Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol. 1996; 70(5):2982-91. PMC: 190157. DOI: 10.1128/JVI.70.5.2982-2991.1996. View

Weissenhorn W, Wharton S, Calder L, Earl P, Moss B, Aliprandis E . The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 1996; 15(7):1507-14. PMC: 450058. View

Feng Y, Broder C, Kennedy P, BERGER E . HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996; 272(5263):872-7. DOI: 10.1126/science.272.5263.872. View

10.

Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M . Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996; 381(6584):661-6. DOI: 10.1038/381661a0. View

11.

Dragic T, Litwin V, Allaway G, Martin S, Huang Y, Nagashima K . HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381(6584):667-73. DOI: 10.1038/381667a0. View

12.

Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath P . The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85(7):1135-48. DOI: 10.1016/s0092-8674(00)81313-6. View

13.

Alkhatib G, Combadiere C, Broder C, Feng Y, Kennedy P, Murphy P . CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996; 272(5270):1955-8. DOI: 10.1126/science.272.5270.1955. View

14.

Bates P . Chemokine receptors and HIV-1: an attractive pair?. Cell. 1996; 86(1):1-3. DOI: 10.1016/s0092-8674(00)80070-7. View

15.

Lambert D, Barney S, Lambert A, Guthrie K, Medinas R, Davis D . Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A. 1996; 93(5):2186-91. PMC: 39932. DOI: 10.1073/pnas.93.5.2186. View

16.

Lawless M, Barney S, Guthrie K, Bucy T, Petteway Jr S, Merutka G . HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry. 1996; 35(42):13697-708. DOI: 10.1021/bi9606962. View

17.

Chen Y, Dierich M . Identification of a second site in HIV-1 gp41 mediating binding to cells. Immunol Lett. 1996; 52(2-3):153-6. DOI: 10.1016/0165-2478(96)02603-x. View

18.

Rabenstein M, Shin Y . HIV-1 gp41 tertiary structure studied by EPR spectroscopy. Biochemistry. 1996; 35(44):13922-8. DOI: 10.1021/bi961743t. View

19.

Chan D, Fass D, Berger J, Kim P . Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997; 89(2):263-73. DOI: 10.1016/s0092-8674(00)80205-6. View

20.

Weissenhorn W, Dessen A, Harrison S, Skehel J, Wiley D . Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997; 387(6631):426-30. DOI: 10.1038/387426a0. View